Provides non-invasive skin diagnostics using tape-stripping and next-generation sequencing to analyze DNA methylation patterns. This technology measures biological aging, inflammation, and UV damage, enabling precise evaluation of therapeutic efficacy and personalized dermatological treatments without the need for invasive biopsies.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IAFounders
Product
Problem
Traditional skin assessment relies on invasive biopsies, which are painful, costly, and can only provide a limited snapshot of the skin's condition. These methods often fail to capture the dynamic changes in skin health influenced by environmental factors, aging, and therapeutic interventions. The lack of non-invasive, comprehensive tools hinders precise evaluation of treatment efficacy and personalized dermatological care.
Solution
Mitra Bio offers a non-invasive skin diagnostics platform that utilizes tape-stripping and next-generation sequencing to analyze DNA methylation patterns, providing a comprehensive view of skin health. This technology enables the measurement of biological aging, inflammation, and UV damage, offering insights into the effectiveness of interventions and the skin's response to environmental factors. By replacing invasive biopsies with a painless tape-stripping method, Mitra Bio allows for easy and robust collection of biological material, facilitating comprehensive in-vivo epigenetic profiling. The platform's extensive database and advanced analytics transform epigenetic data into actionable insights, empowering precision dermatological therapeutics and personalized skincare.
Target Audience
Mitra Bio's primary customers include pharmaceutical companies and aesthetics & skincare brands seeking to evaluate the efficacy of their products, as well as clinical researchers and dermatologists aiming to provide personalized treatments based on comprehensive skin assessment.
Features
- Non-invasive skin sample collection using proprietary tape strips for comprehensive biological material capture.
- Next-generation sequencing to analyze DNA methylation patterns, revealing insights into skin aging, inflammation, and UV damage.
- Epigenetic biomarkers to inform the efficacy of skin therapies and predict optimal responders to specific formulations.
- Measurement of the skin's biological age, inflammation levels, and sun damage through DNA methylation markers.
- Identification of specific genetic factors influenced by topical formulations, providing insights into their impact on skin health and function (e.g., CARD9/11, COL26A1, ZFHX3, OCA3, IRF2BPPL).
- Tracking of methylation changes over time in response to product application or environmental shifts (sun exposure, pollution, hormonal changes).
- Advanced analytics to correlate CpG site methylation with biomarkers for sun-damaged skin.